Bio-Rad Laboratories (NYSE:BIO – Get Free Report) announced its earnings results on Thursday. The medical research company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.99, Briefing.com reports. The company had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.56%. Bio-Rad Laboratories’s revenue was down 6.3% compared to the same quarter last year. During the same period last year, the firm earned $3.00 earnings per share. Bio-Rad Laboratories updated its FY 2024 guidance to EPS.
Bio-Rad Laboratories Stock Performance
BIO traded down $5.32 on Friday, reaching $335.93. The stock had a trading volume of 448,637 shares, compared to its average volume of 240,792. Bio-Rad Laboratories has a 12-month low of $261.59 and a 12-month high of $419.00. The company has a current ratio of 6.57, a quick ratio of 4.89 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $293.21 and its two-hundred day moving average price is $307.67. The company has a market cap of $9.58 billion, a P/E ratio of -32.43 and a beta of 0.93.
Insider Buying and Selling at Bio-Rad Laboratories
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 369 shares of Bio-Rad Laboratories stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the transaction, the executive vice president now owns 6,573 shares of the company’s stock, valued at $1,852,994.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 17.06% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Report on Bio-Rad Laboratories
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Recommended Stories
- Five stocks we like better than Bio-Rad Laboratories
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Best Stocks Under $5.00
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Investing In Preferred Stock vs. Common Stock
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.